ursodiol: profile and news






Axcan announces record revenue of $72.8 million for the second ...  May 4, 2006
NCX-1000 Axcan and its partner, NicOx SA, are developing NCX-1000, a patented, nitric oxide donating derivative of ursodiol, for the treatment of portal ... - Canada NewsWire (press release),

Axcan announces record revenue of $72.8 million for the second ...  May 4, 2006
Axcan and its partner, NicOx SA, are developing NCX-1000, a patented, nitric oxide donating derivative of ursodiol, for the treatment of portal hypertension, a ... - Yahoo! News (press release)


Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org